Non-Insulin Therapies for Diabetes Market Size, Share, By Drug Class (Alpha-Glucosidase Inhibitors, Biguanides, Sulfonylureas Thiazolidinedione’s, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors), By Route of Administration (Oral and Injectable), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy) and By Region - Trends, Analysis and Forecast till 2034

Non-Insulin Therapies for Diabetes Market Size was valued at USD 72.5 Billion in 2024 and is expected to reach USD 145.1 Billion by 2034, growing at a CAGR of 7.20%

Non-insulin therapies are typically used in the treatment for type 2 diabetes patients, where patient’s body unable to produce sufficient insulin or body is incapable to use the insulin it produces. Non-insulin therapies have a different mechanism of action to maintain optimal glycemic control and to reduce blood glucose level. For instance, Sulfonylureas increase the insulin release from pancreatic cells and some agent like alpha-glucosidase inhibitors slow down the digestion of starch in the small intestine.

As of now, rising global incidence and prevalence of diabetes is anticipated to boost the global non-insulin therapies for diabetes market during the forecast period. For instance, according to the International Diabetes Federation’s (IDF), the global prevalence of diabetic accounted for around 425 million, among of 400 million people were suffering from type 2 disease in 2017. Thus, this data represents a high prevalence rate of diabetes across the world, which eventually demand proper treatment management. Therefore, it is expected to propel the global non-insulin therapies for diabetic market within the forecast period.

Key Drivers of Target Market:

Increasing Prevalence of Diabetes and Growing Geriatric Population

• The prevalence of diabetes is expected to reach extremes across the globe. It is estimated that around 463 million people were suffering from diabetes in 2023, and the International Diabetes Federation has projected this to reach 700 million by 2045.  All this increase will be due to the present trends of increasing urbanization, unhealthy lifestyle, and aging populations. As the population of geriatric people increases, this also increases the risk of developing type 2 diabetes. Therefore, these factors raise the demand for an effective solution toward diabetes management and, as a result, non-insulin therapies.
• Treatment for diabetes is undergoing a changing landscape. From the management of blood sugar levels to the control of diabetes-related complications, efforts are focused on addressing such concerns. Keeping in view these aspects, newer non-insulin therapies were designed to add more benefits in terms of weight management or reduction of cardiovascular risk factors like blood pressure or protection against kidney complications. This holistic approach to the management of diabetes yields better outcomes for patients, hence acting as a driver of markets for such new drugs.

Advancements in telehealth and tailored medicine

• Advances in technology are changing the management of diabetes. Telehealth platforms make it easy for patients to open up to consultation and remote monitoring that improve patient adherence. Besides, personalized medicine approaches would individualize treatment plans based on factors like genetics and lifestyle that might result in effective and well-targeted use of non-insulin therapies.
• The need for early diagnosis and intervention in the management of diabetes is increasingly recognized. Early initiation of treatment may have some slowing effect on the development of the disease process, reduce the complications arising from it, and offer the person as a whole a chance to improve their quality of life. This type of emphasis creates a demand for non-insulin therapies in pre-diabetes or early stages of type 2 diabetes, expanding the market beyond traditionally existing patient populations.

Restrains:

High cost implementation

• Despite all the progress in recent years, the high cost of certain non-insulin diabetes medicines represents an access barrier for many patients, particularly where health coverage is thin or out-of-pocket costs are high. This financial burden could lead to poor adherence to medications, thus lowering control of diabetes and increasing associated healthcare costs over time.
• Even access to health facilities, diagnostic tools, and specialists remains poor in socioeconomically disadvantaged populations. This is likely to prevent the early diagnosis of cases and impede access to appropriate treatment including non-insulin therapies. Targeted healthcare efforts must be taken if there has to be equal use of diabetes management solutions to help resolve such inequalities.

Public Misconceptions and Lack of Awareness

• Low public awareness about diabetes and treatment options could result in delayed diagnosis, and thus late initiation of proper treatment. Misconceptions among the public about the type of disease or belief in non-insulin therapies can be prevalent. Therefore, public healthcare campaigns aimed at creating awareness and dissemination of information about diabetes and its treatment process are crucial for the market's growth and early intervention.
• New non-insulin therapies are under stringent regulatory processes for their development and approval. These can be protracted and expensive and hence delay access by patients to such innovative medications. Thereafter, governments and insurance companies are concerned over the containment of health care expenditure. Pricing pressure on pharmaceuticals firms could compromise the affordability of the new medicines, and thus the market access to these drugs by some patients.

Opportunities:

Development of More Affordable Medications, Better Access Programs

• There is an influential need to develop more pocket-friendly non-insulin therapies, particularly in regions with low healthcare budgets. Second, pharmaceutical companies and healthcare providers can team up to work out patient assistance programs that give access to such medications to really needy cases.

Focus on emerging markets and underserved populations

• There exists a huge opportunity for market expansion with an increasing burden of diabetes in developing countries. Focusing on the development of low-cost treatment options, building health infrastructure, and increasing awareness in these geographies would result in manifold growth in the target population.

How Technology Can Help Boost Medication Adherence, Patient Support

• The application of telehealth platforms and mobile apps can make a great contribution to improving medication adherence and providing ongoing support to patients in managing diabetes. These technologies can offer medication reminders, virtual consultations, and access to educational resources.

Further Research and Development in Targeted Therapies

• Reiterating that much more research into new therapies targeting specific patient needs is required, from the control of blood glucose to other added benefits such as pharmacological interventions against specific subtypes of diabetes, individual therapeutic strategies according to genetic background, or treatments aimed at the prevention or slowdown of complications.

Public Awareness Campaigns and Educational Initiatives Collaboration

• There can be collaborative efforts between healthcare organizations, patient advocacy groups, and the pharmaceutical industry toward a more effective public awareness campaign on the prevention of diabetes, its early diagnosis, and the benefits associated with non-insulin therapies.  On the other hand, educational initiatives targeted at healthcare providers will keep them updated with new treatment options and promote the best possible care for patients.

The market is segmented based on Drug Class, Route of Administration, Distribution Channel, and Region.

Drug Class Insights:

• Alpha-Glucosidase Inhibitors: These drugs act entirely differently. They are supposed to slow down the absorption of carbohydrates in the intestine by inhibiting enzymes called alpha-glucosidases. That means blood glucose levels won't go up so quickly after meals and particularly following meals packed with a large quantity of carbohydrates. Alpha-glucosidase inhibitors are usually added to other diabetes medications, but they have possible gastrointestinal side effects, such as bloating and gas.
• Biguanides: This was considered the mainstay of treatment for type 2 diabetes. Metformin clearly has a dual mode of action: it predominantly decreases glucose production by the liver and, to a lesser extent, increases insulin sensitivity to enable cells to take up glucose more effectively. Metformin is very well tolerated and generally carries a low risk of hypoglycemia.
• Sulfonylureas: These drugs increase insulin release from the pancreas. This can be a very good treatment for people who still have sufficient potential to produce insulin. The drawback to these drugs is that sulfonylureas, over some time, lead to weight gain, and at times, hypoglycemic attacks result.
• Thiazolidinediones: These drugs, such as Pioglitazone, act on fat cells to make them more sensitive to insulin, thus contributing to blood sugar control. The Comes with potential side effects of fluid retention and some increased risks for heart failure, TZDs have seen slightly reduced prescription rates.
• DPP-4 Inhibitors: These medications inhibit an enzyme known as Dipeptidyl peptidase-4, which degrades incretin hormones. These are normally produced by the human body to stimulate insulin release and suppress the release of glucagon—a hormone that raises blood sugar. Thus, when DPP-4 is inhibited, more insulin will be available to promote better blood sugar control, accompanied by lower glucagon levels. Generally well-tolerated, DPP-4 inhibitors have additional benefits like weight management in some patients.
• GLP-1 Analogs: Glucagon-like peptide-1 is a gut hormone that has a natural role in blood sugar regulation. GLP-1 analogs are injectable medications which work much like GLP-1 and delay digestion, stimulate the release of insulin, and suppress glucagon secretion, hence ensuring holistic blood sugar control. GLP-1 analogs especially have the advantage of causing weight loss and have been useful in lowering cardiovascular risk in people with type 2 diabetes.
• Sodium-glucose co-transporter-2 inhibitors: This is a thoroughly new class of medications that works in the kidneys. SGLT-2 inhibitors reduce the reabsorption of glucose from the kidneys into the blood; therefore, above-normal glucose is passed out in the urine. This brings down the level of sugar in the blood, and this new approach also brought other fringes such as reducing blood pressure and protection against heart and kidney complications for some patients.

Route of Administration Insights:

• Oral: Most medications to treat non-insulin diabetes are given orally. This, therefore, makes it include metformin, which is a Biguanides, sulfonylureas, thiazolidinediones, and alpha-glucosidase inhibitors, as well as the DPP-4 inhibitors. Oral medications can be quite convenient to take and usually preferred by patients because administration is easy.
• Injectable: Few of these medicines, mainly GLP-1 analogs and some SGLT2 inhibitors are administered through injections. Though less convenient than oral drugs, they have many advantages over oral medications. They may have a more rapid onset of action, longer duration of action, and be more efficacious for some patients.

Distribution Channel Insights:

• Retail pharmacy: This is the most common dispensing channel for non–insulin diabetes medications. Several prescriptions are, therefore, filled by patients at a surrounding pharmacy after issuing them from a doctor.
• Hospital pharmacy: Drugs will be dispensed through a hospital pharmacy in some cases, especially for those newly admitted or requiring intensive treatment changes, during their tenure at the facility.
• Online Pharmacy: Increasingly, people are looking toward Internet pharmacies to get their prescription medications. There is convenience and potentially lower costs in this channel, but with an online pharmacy, it is very important that it is licensed and reputable. Always consult with your doctor before using an online pharmacy.

Regional Insights

• North America: This region holds the largest market share as a result of a number of factors ranging from high prevalence rates of diabetes to advanced healthcare infrastructure, which makes new medications easily accessible to patients. However, a rise in healthcare costs and doubts expressed over the affordability of medicines are some of the challenges.
• Europe: Europe is a large potential market with well-established healthcare systems and rising cases of diabetes. The stringent regulatory procedures delay the introduction of new drugs.
• Asia Pacific: This region accounts for the fastest growth of the market in view of the rapidly rising prevalence of diabetes, mainly in countries like China and India. However, very limited availability of advanced health care facilities and limited per capita expenditure on healthcare might sometimes act as the growth restraining factor.
• Latin America: The region is likely to grow at a stable rate on the back of increasing disposable incomes and rising awareness of diabetes. Underdeveloped healthcare infrastructure and limited access to medications in some countries are acting as growth deterrents.
• Middle East and Africa holds a minor market share. However, the prevalence of diabetes is on an increasing trend, and economic development in these regions is an opportunity for this market, in future. Poor accessibility to diagnostics, lack of good healthcare facilities, and economic constraints to spend on these kinds of diagnostic devices are somewhat significant challenges.

Non-Insulin Therapies for Diabetes Market Report Scope:

Attribute	Details
Market Size 2024	US$ 72.5 billion
Projected Market Size 2034	US$ 145.1 billion
CAGR Growth Rate	7.20%
Base year for estimation	2023
Forecast period	2024 – 2034
Market representation	Revenue in USD Billion & CAGR from 2024 to 2034
Market Segmentation	By Drug Class- Alpha-Glucosidase Inhibitors, Biguanides, Sulfonylureas, Thiazolidinedione, DPP-4 Inhibitors, GLP-1 Analogs, and Sodium-glucose co-transporter-2 (SGLT2) inhibitors By Route of Administration- Oral and Injectable By Distribution Channel- Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy
Regional scope	North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends

Segments Covered in the Report:

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2024 to 2034. For the purpose of this study segmented the target market report based on By Drug Class, Route of Administration, Distribution Channel, and Region.

By Drug Class:

• Alpha-Glucosidase Inhibitors
• Biguanides
• Sulfonylureas
• Thiazolidinedione
• DPP-4 Inhibitors
• GLP-1 Analogs
• Sodium-glucose co-transporter-2 (SGLT2) inhibitors

By Route of Administration:

• Oral
• Injectable

By Distribution Channel:

• Retail Pharmacy
• Hospital Pharmacy
• Online Pharmacy

By Region:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Russia
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • Israel
  • South Africa
  • Rest of Middle East & Africa

The key players operating the Non-Insulin Therapies for Diabetes Market include AstraZeneca, Bristol-Myers Squibb, BoehringerIngelheim GmbH, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Merck and Company, Janssen Pharmaceuticals, Novartis AG, Sanofi Aventis, Novo Nordisk, Pfizer and Takeda Pharmaceuticals.

• In March 2023, Sanofi India has just received the green light from the Central Drugs Standard Control Organization for selling its diabetes drug, SoliquaTM. This prefilled pen drug is designed to provide improved glycemic control in people with type 2 diabetes and obesity who have not achieved adequate control with either oral or injectable therapy. Soliqua is given once a day through pre-filled pens containing a fixed-ratio combination of insulin glargine and lixisenatide in two different ratios: 10-40 and 30-60.
• In November 2022, AstraZeneca India gets nod to market anti-diabetes drug Dapagliflozin. The company said that it had received permission from the Central Drugs Standard Control Organization for the drug indicated for diabetes patients with chronic kidney disease or CKD.

• AsteaZenca
  • Company Overview
  • Product Portfolio
  • Key Highlights
  • Financial Performance
  • Business Strategies
• Bristol-Myers Squibb
• Boehringerlngelheim GmbH
• Eli Lilly
• F.Hoffmann-La Roche LTD.
• GlaxoSmithKline
• Merck and Company
• Janssen Pharmaceuticals
• Novartis AG
• Sanofi Aventis

“*” marked represents similar segmentation in other categories in the respective section.

Research Objective and Assumption

• Research Objectives
• Assumptions
• Abbreviations

Market Preview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Drug Class
  • Market Snippet, By Route of Administration
  • Market Snippet, By Distribution Channel
  • Market Snippet, By Region
• Opportunity Map Analysis

Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Market Trends
• Product Launch
• Merger and Acquisitions
• Impact Analysis
• PEST Analysis
• Porter’s Analysis

Market Segmentation, Drug Class, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Alpha-Glucosidase Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Biguanides
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Sulfonylureas
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• Thiazolidinedione
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• DPP-4 Inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends
• GLP-1 Analogs
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Segment Trends

• Sodium-glucose co-transporter-2 (SGLT2) inhibitors
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
  • Segment Trends

Market Segmentation, Route of Administration, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Injectable
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years

Market Segmentation, Distribution Channel, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Segment Trends
• Retail Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Hospital Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Online Pharmacy
  • Overview
  • Market Size and Forecast (US$ Bn), and Y-o-Y Growth (%), Forecast Period up to 10 Years
• Residential

Market Segmentation, By Region, Forecast Period up to 10 Years, (US$ Bn)

• Overview
  • Market Value and Forecast (US$ Bn), and Share Analysis (%), Forecast Period up to 10 Years
  • Y-o-Y Growth Analysis (%), Forecast Period up to 10 Years
  • Regional Trends
• North America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • U.S
    • Canada
• Asia Pacific
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • India
    • Japan
    • South Korea
    • China
    • Rest of Asia Pacific
• Europe
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • UK
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
• Latin America
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • Brazil
    • Mexico
    • Rest of Latin America
• Middle East and Africa
  • Market Size and Forecast (US$ Bn), By Drug Class, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Route of Administration, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Distribution Channel, Forecast Period up to 10 Years
  • Market Size and Forecast (US$ Bn), By Country, Forecast Period up to 10 Years
    • GCC
    • Israel
    • South Africa
    • Rest of Middle East and Africa

Competitive Landscape

• Heat Map Analysis
• Company Profiles

• AsteaZenca
• Bristol-Myers Squibb
• Boehringerlngelheim GmbH
• Eli Lilly
• F.Hoffmann-La Roche LTD.
• GlaxoSmithKline
• Merck and Company
• Janssen Pharmaceuticals
• Novartis AG
• Sanofi Aventis

The Last Word

• Future Impact
• About Us
• Contact